Sirius Investors
46.86
1.37%Today
Market Cap
95.36B
Volume
9.45M
52W High
63.33
52W Low
44.00

No historical price data available

No price history data available for the selected time period.

Try selecting a different time range.

Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Company Information

CEO
Christopher S. Boerner
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
34100

Contact Information

Address
430 East 29th Street
Country
US

Investment Analysis & Insights

Key Investment Highlights

  • Market Position: Healthcare leader with 95.36B market capitalization
  • Trading Volume: 9.45M shares traded today
  • Price Range: 52-week range of $44.00 - $63.33
  • Exchange: Listed on New York Stock Exchange

Financial Metrics

P/E Ratio:17.49
EPS:$2.68
Beta:0.37
Avg Volume:13.98M

Market Analysis for Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (BMY) operates in the Drug Manufacturers - General industry within the Healthcare sector. With a current market capitalization of 95.36B, the company represents a significant player in its market. The stock is currently trading at $46.86 with a negativedaily change of 1.37%.

The company's 34100 employee base and presence on the New York Stock Exchangeexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 17.49, beta of 0.37, and 52-week price range from $44.00 to $63.33when evaluating investment opportunities.

Why Invest in Bristol-Myers Squibb Company?

Strengths
  • • Established market presence in Healthcare
  • • Strong financial metrics and market position
  • • Listed on major exchange (New York Stock Exchange)
  • • Experienced leadership under Christopher S. Boerner
Investment Considerations
  • • Monitor sector-specific market trends
  • • Track quarterly earnings performance
  • • Consider market volatility and beta
  • • Evaluate long-term growth potential